Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, La Jolla, CA 92093, USA.
Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA 91010, USA.
Viruses. 2024 Aug 14;16(8):1294. doi: 10.3390/v16081294.
The acquisition or reactivation of Epstein-Barr virus (EBV) after allogeneic Hematopoietic Stem Cell Transplant (HSCT) can be associated with complications including the development of post-transplant lymphoproliferative disorder (PTLD), which is associated with significant morbidity and mortality. A number of risk factors for PTLD have been defined, including T-cell depletion, and approaches to monitoring EBV, especially in high-risk patients, with the use of preemptive therapy upon viral activation have been described. Newer therapies for the preemption or treatment of PTLD, such as EBV-specific cytotoxic T-cells, hold promise. Further studies to help define risks, diagnosis, and treatment of EBV-related complications are needed in this at-risk population.
异基因造血干细胞移植（HSCT）后 EBV 的获得或再激活可导致多种并发症，包括移植后淋巴增殖性疾病（PTLD），这与较高的发病率和死亡率相关。目前已经确定了 PTLD 的多个危险因素，包括 T 细胞耗竭，以及监测 EBV 的方法，特别是在高危患者中，通过病毒激活时的抢先治疗已被描述。针对 PTLD 的抢先治疗或治疗的新疗法，例如 EBV 特异性细胞毒性 T 细胞，具有一定的前景。在这个高危人群中，需要进一步的研究来帮助确定 EBV 相关并发症的风险、诊断和治疗。
